Atria Investments Inc Sells 323 Shares of Integer Holdings Co. (NYSE:ITGR)

Atria Investments Inc cut its holdings in Integer Holdings Co. (NYSE:ITGR) by 5.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 6,105 shares of the medical equipment provider’s stock after selling 323 shares during the quarter. Atria Investments Inc’s holdings in Integer were worth $794,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Contravisory Investment Management Inc. boosted its position in shares of Integer by 55.9% in the 3rd quarter. Contravisory Investment Management Inc. now owns 223 shares of the medical equipment provider’s stock worth $29,000 after purchasing an additional 80 shares during the last quarter. Quest Partners LLC grew its position in shares of Integer by 3,688.9% during the 2nd quarter. Quest Partners LLC now owns 341 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 332 shares during the period. GAMMA Investing LLC increased its stake in shares of Integer by 60.9% in the 2nd quarter. GAMMA Investing LLC now owns 375 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 142 shares during the last quarter. Innealta Capital LLC acquired a new stake in shares of Integer in the 2nd quarter valued at approximately $110,000. Finally, Hancock Whitney Corp bought a new position in Integer during the 1st quarter worth approximately $203,000. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Stock Performance

Shares of Integer stock opened at $134.55 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.28 and a quick ratio of 2.09. The firm has a market cap of $4.51 billion, a price-to-earnings ratio of 41.10, a price-to-earnings-growth ratio of 1.91 and a beta of 1.09. The stock’s 50-day moving average is $129.20 and its 200-day moving average is $122.75. Integer Holdings Co. has a one year low of $84.75 and a one year high of $140.91.

Integer (NYSE:ITGR) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $1.43 EPS for the quarter, beating the consensus estimate of $1.36 by $0.07. The firm had revenue of $431.42 million for the quarter, compared to analysts’ expectations of $440.59 million. Integer had a return on equity of 11.63% and a net margin of 6.70%. The business’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.27 EPS. Equities analysts predict that Integer Holdings Co. will post 5.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ITGR has been the subject of several recent analyst reports. KeyCorp upped their target price on shares of Integer from $139.00 to $144.00 and gave the company an “overweight” rating in a research note on Tuesday, October 15th. Citigroup upped their price objective on shares of Integer from $124.00 to $130.00 and gave the company a “neutral” rating in a research report on Tuesday, October 1st. Bank of America raised their price objective on Integer from $135.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, October 1st. Truist Financial decreased their target price on Integer from $150.00 to $147.00 and set a “buy” rating for the company in a research note on Friday, October 25th. Finally, Benchmark raised their price target on Integer from $130.00 to $140.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Integer currently has a consensus rating of “Moderate Buy” and a consensus price target of $139.75.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.